A DNA treatment joins the effort to spare patients repeated airway surgery

Adults with recurring airway tumors can spend years moving between surgery, recovery and the next operation. Voceryq, granted accelerated approval by the U.S. Food and Drug Administration on October 30, aims to reduce that surgical burden by directing an immune response toward the HPV-infected cells involved in recurrent respiratory papillomatosis, or RRP. [1]

The approval opens a commercial path for Inovio Pharmaceuticals’ plasmid-DNA technology. It also adds a treatment choice in a disease where another immune-based therapy, Papzimeos, received FDA approval in August 2025. Voceryq’s distinction is the first U.S. approval for a plasmid-DNA immunotherapy. Patients and clinicians will need to weigh how each option performs over time and fits into existing care. [1,6]

Why reducing surgery matters

RRP produces growths in the respiratory tract, commonly around the voice box. The disease can affect speech and breathing. According to the National Institute on Deafness and Other Communication Disorders, the frequency of surgery varies substantially: some patients need procedures every few weeks, while others need them annually or less often. [2]

An operation can remove growths and help keep the airway open. Recurrent disease brings patients back into a cycle of monitoring and treatment. A longer interval between procedures could ease the demands of scheduling, recovery and disrupted daily life. The importance of that interval depends on the person’s disease severity, voice requirements, breathing symptoms and treatment history.

Counting operations captures one major burden of RRP. Assessing a treatment also means following patients’ voice, breathing and quality of life, the persistence of benefit, and the risks of the treatment itself.

A drug and device developed together

Voceryq uses small DNA molecules called plasmids to deliver instructions to cells. One component supplies instructions for proteins associated with HPV types 6 and 11; another supplies instructions for IL-12, a molecule that helps stimulate immune activity. The intended result is an immune response directed at infected cells. [9]

Delivery requires more than a conventional injection. The treatment uses Inovio’s CELLECTRA 5PSP device to apply brief electrical pulses, temporarily increasing the ability of cell membranes to take up the DNA. The FDA prescribing information describes four intramuscular doses at three-week intervals, with surgical removal of visible disease before treatment and administration by trained health professionals. [3]

A clinic offering the treatment needs the medicine, the delivery device, trained staff and a plan for the full course. The drug also requires refrigerated storage. Those requirements make treatment-center readiness part of the commercial rollout. [3]

Inovio is the developer. The research program involved U.S. clinical institutions, including NYU Langone in New York and Mayo Clinic in Arizona, whose trial listings describe participation in the RRP study. The clinical results were published in Nature Communications in February 2025. The program brought the treatment into a multicenter patient study. [4,5,8]

What the patient evidence establishes

The FDA describes an open-label study involving 32 adults. In the subset of 26 participants with at least three surgeries in the preceding 12 months, seven, or 27 percent, required no surgical intervention during the first year after treatment. The result applies to that defined subgroup within the trial. [1]

An open-label, single-arm study gives researchers a record of outcomes after treatment, with participants’ prior disease history providing context. Comparing those periods raises questions about the natural course of disease and decisions to operate. Additional evidence helps establish how reliably the treatment accounts for the observed changes and which patients are most likely to benefit. [8]

The FDA used reduced surgical frequency as an intermediate clinical endpoint reasonably likely to predict benefit. Accelerated approval requires post-approval trials to verify and describe the clinical benefit. Longer follow-up will help clarify durability and whether patients need further treatment. [1]

Approval opens the way to clinical use while placing an obligation on the manufacturer to verify the clinical benefit.

How it fits alongside another approved therapy

Papzimeos, developed by Precigen, received FDA approval on August 14, 2025, for adults with RRP. It uses a non-replicating adenoviral-vector approach to stimulate an immune response. Voceryq uses plasmid DNA and an electrical delivery device. Both belong to the effort to address the disease through immune activity, using different delivery systems. [6,9]

With two immune-directed treatments approved, clinicians must consider how to choose among them and fit them into a patient’s care. Each product has its own prescribing information, evidence base and administration requirements. Separate trials involve different populations and assessment conditions; a treatment ranking would require a sound comparative basis.

Safety and access will shape the rollout

The FDA lists injection-site reactions, headache, fatigue, hypertension, nausea and dizziness among common adverse reactions. Electrical delivery can also cause muscle contractions, local pain or bleeding and lightheadedness, among other effects. These considerations belong in the clinical discussion alongside the possibility of fewer operations. [3]

Inovio said on October 30 that it expected initial ordering and shipping in approximately 60 days, followed by a full commercial launch in the first quarter of 2027. Those dates describe the company’s rollout expectations. Access will also depend on equipped treatment centers and coverage arrangements. [7]

A practical assessment of affordability requires a verified price, the cost of administering the course and the patient’s coverage terms. Published launch timing alone leaves those questions open. For health systems, any potential reduction in future procedures must be considered alongside treatment expense, clinical outcomes and the length of benefit.

Routine care will test how the first approved plasmid-DNA immunotherapy performs across a broader patient population. Success in RRP could inform development of the platform, while applications in other diseases will require their own clinical evidence. For the adults considering Voceryq, the immediate questions are how long it controls their disease, what treatment involves and whether they can obtain it.